Physician profile
Nicole E Burrows
NPI 1689612004
$3,224.85
in general payments reported to CMS, 2019-2025
24 companies · $827 in 2025
The $827 reported for 2025 was more than what 80% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $416 · 2022: $612 · 2023: $516 · 2024: $854 · 2025: $827.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,196.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,196.37 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $865.75 | 2021-2025 | Keytruda, Lynparza, Keytruda Qlex |
| Astrazeneca Pharmaceuticals LP | $434.79 | 2021-2025 | Lynparza |
| Eisai INC. | $329.51 | 2021-2025 | |
| Glaxosmithkline, LLC. | $291.86 | 2022-2025 | Jemperli, Zejula |
| Abbvie INC. | $208.42 | 2024-2025 | |
| Pfizer INC. | $160.71 | 2024-2025 | |
| Seagen INC. | $141.56 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $137.16 | 2023-2024 | |
| Clovis Oncology, INC. | $104.94 | 2021-2022 | |
| Amneal Pharmaceuticals LLC | $75.31 | 2023-2024 | Avastin, Neulasta, Neupogen |
| Janssen Biotech, INC. | $61.67 | 2025 | Rybrevant, Darzalex, Talvey |
| Astellas Pharma US INC | $50.84 | 2023-2024 | Veozah |
| Myriad Genetic Laboratories, INC. | $48.03 | 2022 | |
| Amgen INC. | $41.33 | 2021-2022 | |
| Menarini Silicon Biosystems, INC. | $38.48 | 2025 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Immunogen, INC. | $35.58 | 2023 | Elahere |
| Beone Medicines USA, INC. | $34.96 | 2025 | Brukinsa |
| Lilly USA, LLC | $32.40 | 2025 | Verzenio |
| Coherus Oncology, INC. | $31.35 | 2023 | |
| Incyte Corporation | $23.16 | 2025 | Zynyz, Monjuvi |
| Spectrum Pharmaceuticals INC. | $22.48 | 2025 | Rolvedon |
| Aspira Women'S Health INC | $19.80 | 2024 | Ova1 |
| Foundation Medicine, INC. | $18.65 | 2021 | |
| Fennec Pharmaceuticals, INC. | $16.11 | 2024 | Pedmark |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nicole Burrows listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.